Core Points - Scorpius Holdings, Inc. has received notice from NYSE American regarding the commencement of delisting proceedings due to the low selling price of its common stock [1] - The company is also noncompliant with NYSE American's continued listing standards due to the failure to timely file its Form 10-K for the year ended December 31, 2024 [2] - Scorpius plans to appeal the delisting decision and request a review from the Exchange's Listings Qualifications Panel [3] - The CEO of Scorpius emphasized the company's commitment to regulatory compliance and transparency while working towards maximizing long-term shareholder value [4] Company Overview - Scorpius Holdings, Inc. is an integrated contract development and manufacturing organization (CDMO) focused on advancing biologic and cell therapy programs [4] - The company provides a range of analytical testing, process development, and manufacturing services to pharmaceutical and biotech companies from its facilities in San Antonio, TX [4]
Scorpius Holdings Receives NYSE American Notice of Delisting and Reports Plans to Appeal